

# Monoclonal Antibody to CD20, FITC conjugated (CD20 FITC)

Cat.No. ED7005

### 1. Intended purpose

The reagent CD20 FITC permits identification and enumeration of cell populations expressing human CD20 antigen in whole blood using flow cytometry.

### 2. Test principle

This test is based on specific binding of monoclonal antibody to the antigenic determinant expressed on the surface of leukocytes. The monoclonal antibody is labeled with fluorochrome which is excited via laser beam from a flow cytometer during analysis. Subsequent emission of light from fluorochromes of each cell is collected and analyzed by a flow cytometer. The fluorescence intensity differences enable separation of cell subsets based on expression of analyzed antigen. Specific staining of blood cells is performed by incubation of blood samples with the reagent followed by a lysis of red blood cells. Afterwards, unaffected leukocytes are subjected to analysis by a flow cytometer.

### 3. Reagents provided

The reagent contains mouse monoclonal antibody against human CD20 antigen (clone LT20) which was purified by affinity chromatography and labeled with Fluorescein isothiocyanate (FITC). The labeled antibody is diluted in an optimal concentration in stabilizing phosphate buffered saline (PBS) solution containing 15mM sodium azide. The content of a vial (2 ml) is sufficient for 100 tests.

### Product specification

|                  |                 |
|------------------|-----------------|
| Content          | 100 tests, 2 ml |
| Usage            | 20 µl per test  |
| Specificity      | Human CD20      |
| Clone            | LT20            |
| Isotype          | Mouse IgG2a     |
| Fluorochrome     | FITC            |
| λ excitation     | 488 nm          |
| Emission maximum | 525 nm          |

### 4. Materials required but not provided

Test tubes for blood staining (e.g. 12 × 75 mm)  
Commercial lysing solution  
Phosphate buffered saline (PBS)  
Isotype control antibody (mouse IgG2a FITC)

### 5. Equipment required

Automatic pipettes with disposable tips  
Vortex mixer  
Centrifuge  
Flow cytometer with excitation laser 488 nm and proper filters

### 6. Storage and handling

Store the vial at 2 - 8 °C. Keep away from sunlight. Do not freeze. Do not aliquote. Expiration date is stated on a vial label and on outer packaging.

### 7. Warnings, precautions and limitations of use

- Intended for In Vitro Diagnostic use in laboratories outside USA and Canada. This CE-IVD reagent is in conformity with the European Directive 98/79/EC.
- Do not use reagent after expiration date.
- Avoid reagents contamination.
- Avoid prolonged exposure to light.
- The content of the vial must not freeze.
- Any non-performance of staining protocol may produce false results.
- The reagent contains sodium azide (NaN<sub>3</sub>) which is highly toxic in pure form. However, the concentration in the reagent (15mM) is not considered as hazardous. When disposing the reagent, flush the sink with a large volume of water.
- Blood samples are considered as potentially infectious and must be handled with care. Avoid all contact of the sample with the skin, eyes and mucosa.
- In case of hyperleukocytose sample, it is recommended to dilute blood sample with PBS to obtain leukocyte density approximately 5 × 10<sup>5</sup> leukocytes/ml.
- Blood samples from abnormal patients may exhibit abnormal values of positive cells.
- Data may be incorrectly interpreted if fluorescent signals were compensated

wrongly or if gates were positioned inaccurately.

- Flow cytometer may produce false results if the device has not been aligned and maintained appropriately.
- Red blood cells from abnormal patients may be resistant to lysis using lysing solutions.
- Blood samples should be stained and analyzed within 24 hours from the blood collection.

### 8. Specimen

Use the peripheral human blood in a sterile tube with an anticoagulant (Heparin or EDTA). Blood must be stored at room temperature.

### 9. Procedure


#### Staining protocol

- Add 20 µl of CD20 FITC reagent to a test tube, and the necessary amount of isotype control to a control tube.
- Add 100 µl of blood sample to each tube. Vortex the tubes.
- Incubate tubes for 20 - 30 minutes at room temperature in the dark.
- Perform lysis of red cells using lysing solution. It is recommended to use a commercial lysing solution containing formaldehyde as a fixative. Follow the instructions of the lysing solution manufacturer.
- Centrifuge tubes for 5 minutes at 300 g.
- Remove supernatant and resuspend pellet with 3 - 4 ml of PBS.
- Centrifuge tubes for 5 minutes at 300 g.
- Remove supernatant and resuspend pellet with 0.3 - 0.5 ml of PBS.
- Analyze samples immediately using flow cytometer or store samples at 2 - 8 °C in the dark and analyze within 24 hours provided that cells were fixed.

#### Flow Cytometric Analysis


Analyze the sample stained with CD20 FITC using a flow cytometer. Visualize recorded data on the side-scatter (SSC) versus forward-scatter (FSC) plot. Set the gate for lymphocyte population as shown in figure 1.

Fig. 1: Delimitation of lymphocyte population



Then make a histogram of lymphocytes with FITC intensity on the x-axis as shown in figure 2. Separate positive and negative populations using appropriate gates and calculate the percentage of CD20 positive lymphocytes. The region corresponding to the negative population should be set up using control cells which were stained by isotype control antibody.

Fig. 2: Lymphocytes stained with CD20 FITC reagent



### 10. Analytical performance

#### Specificity

The monoclonal antibody LT20 reacts with CD20 (Bp35), a 33-37 kDa non-glycosylated membrane tetraspan phosphoprotein involved in store-operated calcium entry. It is expressed on B lymphocytes (lost on plasma cells), follicular dendritic cells, and at low levels on peripheral blood T lymphocytes.

### 11. Clinical performance

#### Expected values

Results obtained in different laboratories may vary. Each laboratory should establish a normal range of cell subsets using its own test conditions. Results obtained in our laboratory are given in the table below.

| Parameter                     | Mean (%) | SD  | CV (%) |
|-------------------------------|----------|-----|--------|
| CD20 <sup>+</sup> lymphocytes | 12.0     | 4.8 | 40.0   |

### 12. References

Glennie MJ et al. (2007) Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol. 44: 3823-37

Teeling JL et al. (2006) The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol. 177: 362-71

Cragg MS et al. (2005) The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun. 8: 140-174

Janas E et al. (2005) Functional role of lipid rafts in CD20 activity? Biochem Soc Symp. 72: 165-75

Li H et al. (2004) The CD20 calcium channel is localized to microvilli and constitutively associated with membrane rafts. J Biol Chem. 279: 19893-19901

Chan HT et al. (2003) CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts. Cancer Res. 63: 5480-9

Petrie RJ and Deans JP (2002) Colocalization of the B cell receptor and CD20 followed by activation-dependent dissociation in distinct lipid rafts. J. Immunol. 169: 2886-2891

Polyak MJ et al. (2002) Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure. Blood. 99: 3256-62

### 13. Manufacturer

EXBIO Praha, a.s.  
Nad Safinou II 341  
25250 Vestec  
Czech Republic

info@exbio.cz  
technical@exbio.cz  
orders@exbio.cz  
www.exbio.cz

### 14. Trademarks

N/A

### 15. Revision History

- Version 1, ED7005\_IFU\_v1  
Initial Release
- Version 2, ED7005\_IFU\_v2  
Merging three language mutations into one document.
- Version 3, ED7005\_IFU\_v3  
The address was changed: "Nad Safinou II 341".
- Version 4, ED7005\_IFU\_v4  
Precautions section was changed - "Intended for professional use only." - removed. "Intended for In Vitro Diagnostic use in laboratories outside USA and Canada. This CE-IVD reagent is in conformity with the European In Vitro Diagnostic Medical Device Directive 98/79/EC." - added.
- Version 5, ED7005\_IFU\_v5  
Reagent provided section was changed: text "stabilizing" added, "solution" - added and "0.2% (w/v) high-grade protease free Bovine Serum Albumin (BSA) as a stabilizing agent" - removed.
- Version 6, ED7005\_IFU\_v6  
The company logo changed. IFU layout changed. "Keep away from sunlight." - added. Postal code changed: "25250 Vestec"



## Monoclonal Antibody to CD20, FITC conjugated (CD20 FITC)

**100 tests** | Cat.No. **ED7005**



### Instructions for Use

Version: ED7005\_IFU\_v6\_EN

Date of Issue: 15-06-2020

EN

### Symbols



Catalogue number



Batch code



Use-by date



Temperature limits



Keep away from sunlight



In vitro diagnostic medical device



CE marking of conformity



Consult instructions for use



Manufacturer

The product is intended for In Vitro Diagnostic Use. In vivo diagnostic or therapeutic applications are strictly forbidden.

Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s.

EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at [www.exbio.cz](http://www.exbio.cz). EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s..